Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces superior weight loss and glycemic control compared to placebo, semaglutide, and insulin in patients with type 2 diabetes and obesity.
Tirzepatide is a once-weekly injection for type 2 diabetes and obesity that works by mimicking two gut hormones (GLP-1 and GIP). It is more effective than single-hormone drugs and insulin for lowering blood sugar and losing weight. Common side effects like nausea usually improve over time. It is not for type 1 diabetes or those with a history of pancreatitis.
In clinical studies, SURPASS has shown good efficacy in reducing glycated hemoglobin and reducing weight. It therefore appears to be a promising drug both in the treatment of type 2 DM and obesity.
Why this rating
Based on multiple Phase 3 randomized controlled trials (SURPASS-1 through 5, SURMOUNT-1) with large sample sizes and statistically significant results.
Source
Tirzepatid - a new hope in the treatment of obesity and a new antidiabetic drug
Robert Prosecký et al. · Klinická farmakologie a farmacie · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →